Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Content from other channels on our network

Review proposes major health system changes

Private Health CEO Forum to tackle financial viability issues

Medline introduces Namic Ready Set Kits

Solventum innovations enabling better, smarter, safer healthcare

Lumia Care expands national network with SA acquisition

Pacific Automation: Automation Components and Solutions for Australia's Food Processing Industry

What's New in Palletising

Scooping Up Success: Sajani Cups and Cones Freezes Out Stock Issues with Fishbowl

Managing Food Safety Risk Efficiently with Data Automation

Introducing Tool-Free Mounting and Reduced Service Times with Bürkert's Direct Acting Service Valves

Orica cuts particle emissions from Kooragang Island site by around 95%

CSIRO's new facility for printed flexible solar techology

Driving change: how electric vehicles are fuelling Australia's sustainable businesses

CSIRO gathers innovators to tackle plastic waste

Trinasolar launches agrivoltaics project in NZ